8 news items
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY
14 May 24
to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
INCY
13 May 24
, including expenses relating to litigation or strategic activities; further research and development and the results of clinical trials possibly being
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY
30 Apr 24
developments in and risks related to: further research and development and the results of clinical trials possibly being unsuccessful or insufficient
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
INCY
10 Mar 24
to patients in need.
Our research and development efforts in dermatology are initially focused
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY
10 Mar 24
solutions to patients in need.
Our research and development efforts in dermatology are initially focused
sba0i9zfkg33o2g19xkmtisskflf347 ew61hfm29ngdxbc4le4i73
INCY
4 Mar 24
.
Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT
jyxl76p49q522xwj0y7w0w
INCY
29 Feb 24
delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory
nddb2ju4jthw wz70
INCY
SNDX
27 Feb 24
in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful
- Prev
- 1
- Next